|
Drug-Eluting Stent Summit Announced
for TCT 2009 Meeting in San Francisco
|
 |
 |
|
September
15, 2009 -- Over
16 hours of presentations on drug-eluting stents will kick off
next week's TCT meeting, billed as the largest global medical
and scientific symposium dedicated to interventional cardiovascular
medicine. The annual week-long meeting is being held at the Moscone
Center in San Francisco this year, and will return to its regular
venue in Washington DC in 2010.
Organizers expect attendance
of more than 10,000 medical professionals, industry representatives
and financial analysts. |
Following is the schedule for the Drug-Eluting Stent Summit, being
held on Monday September 21
from
8:00am to 6:40pm
and
Tuesday,
September
22 from 1:00pm to 6:30pm:
The
Drug-Eluting Stent Summit Part 1:
Appropriate Utilization of Current
Generation
Devices
Monday, September 21, 2009 -- 8:00am-6:40pm
Room: 104
Session I. DES Use Patterns: Aerial
Perspectives
| 8:00am |
|
The Global Landscape for DES Utilization
Lecturer: Sigmund Silber |
DES vs. BMS Use Considerations
| 8:10am |
|
Comprehensive Meta-Analysis
of the Published Literature Suggests a DES Clinical
Advantage
Presenter: Ajay J. Kirtane
|
| 8:20am |
|
Results from the ACC-NCDR "Real-World" PCI
Database Comparing DES and BMS
Presenter: Ralph G.
Brindis
|
| 8:30am |
|
Recent DES Health Economics
Analyses: Does the Cost-Value Equation Still Favor
DES?
Presenter: David J. Cohen
|
| 8:40am |
|
Discussion with Audience
Q&A
Panel
Moderators: Marie-Claude Morice, David O. Williams
Discussants: Jorge A. Belardi, Ralph G. Brindis,
David J. Cohen, Junbo Ge, Peter Juni, Sigmund Silber,
Mark A. Turco |
Session II. Controversial DES
Clinical Indications
DES in Multivessel Disease (vs. CABG)
Moderators: Antonio Colombo,
Michael J. Mack
| 8:52am |
|
Multivessel Disease Lessons From SYNTAX (Early Results
and 2 Year Follow-Up): Surgery Perspectives Lecturer: Friedrich
W. Mohr
|
| 9:00am |
|
Multivessel Disease Lessons From SYNTAX (Early Results and
2 Year Follow-Up): Interventional Perspectives
Lecturer: Marie-Claude
Morice
|
| 9:08am |
|
Case Presentation: Multivessel Disease - CABG or DES?
Case
Presenter: Alaide Chieffo
|
| 9:14am |
|
Discussion with Audience Q&A Panel
Moderators: Antonio Colombo,
Michael J. Mack Discussants: Alaide Chieffo, Jean Fajadet, John
M. Lasala, Friedrich W. Mohr, Marie-Claude Morice, Christian
M. Spaulding
|
DES in Unprotected Left Main Disease (vs. CABG)
Moderators: Joseph
F. Sabik, Marco Valgimigli
| 9:24am |
|
Left Main Lessons from SYNTAX (Early Results and 2 Year Follow-Up):
Surgery Perspectives
Presenter: Michael J. Mack
|
| 9:32am |
|
Left Main Lessons from SYNTAX (Early Results and 2 Year Follow-Up):
Interventional Perspectives
Presenter: Patrick W. Serruys
|
| 9:40am |
|
Is There an Optimal DES Technique for Unprotected Left Main
Lesions?
Presenter: Paul S. Teirstein
|
| 9:50am |
|
Results from an Ongoing Multicenter Everolimus-Eluting Stent
Registry in Unprotected Left Main Disease
Presenter: Olivier
Darremont
|
| 10:00am |
|
Case Presentation: Unprotected Left Main Disease - DES or CABG?
Presenter:
Raj Makkar
|
| 10:08am |
|
Discussion with Audience Q&A
Presenters: Olivier Darremont,
Eulogio Garcia, Michael J. Mack, Raj Makkar, Seung-Jung Park,
Joseph F. Sabik, Ashok Seth, Gregg W. Stone, Paul S. Teirstein,
Marco Valgimigli
|
| 10:20am |
|
Flash Debate 1: Should the SYNTAX Score Guide PCI Strategy
in Complex Lesion Subsets? A Valuable New Standard Has Been Established!
Presenter:
Patrick W. Serruys
|
| 10:28am |
|
Flash Debate 1: Should the SYNTAX Score Guide PCI Strategy
in Complex Lesion Subsets? It Is Too Complicated for Me, the "Eyeball
Test" Is Just as Good!
Presenter: Antonio Colombo
|
| 10:36am |
|
Discussion with Audience Q&A
Presenters: Antonio Colombo, Seung-Jung
Park, Joseph F. Sabik, Patrick W. Serruys, Corrado Tamburino,
Marco Valgimigli
|
DES in Diabetics (vs. Medical Rx or CABG)
Moderators: Frederick
Feit, Dean J. Kereiakes
| 10:45am |
|
Perspectives from BARI 2D: The Case for Medical Therapy First
Presenter:
William E. Boden
|
| 10:53am |
|
Perspectives from BARI 2D: The Case for CABG
Presenter: David
Taggart
|
| 11:01am |
|
Perspectives from BARI 2D: The Case for Appropriate Revascularization
(PCI or CABG)
Presenter: Jeffrey W. Moses
|
| 11:09am |
|
DES vs. Surgery in Diabetics: Insights from CARDIA, SYNTAX,
and Beyond
Presenter: Kevin J. Beatt
|
| 11:19am |
|
Case Presentation: A Diabetic with Multivessel Disease - Medical
Therapy, DES, or CABG?
Presenter: Frederick Feit
|
| 11:27am |
|
Discussion with Audience Q&A
Presenters: Kevin J. Beatt, William
E. Boden, Mark W. Connolly, Michael E. Farkouh, Frederick Feit,
Liliana R. Grinfeld, Dean J. Kereiakes, Neal S. Kleiman, Laura
Mauri, Jeffrey W. Moses, Thomas D. Stuckey, David Taggart
|
DES in Acute Myocardial Infarction (vs. BMS)
Moderators: Cindy L. Grines,
Christian M. Spaulding
| 11:39am |
|
Lessons from HORIZONS: When to Select DES vs. BMS in STEMI
- Clinical and Angiographic Considerations
Presenter: Dariusz
Dudek
|
| 11:49am |
|
A Systematic Meta-Analysis of DES vs. BMS in STEMI
Presenter:
Somjot S. Brar
|
| 11:59am |
|
Case Presentation: Stent Selection in STEMI
Presenter: Giuseppe
De Luca
|
| 12:05pm |
|
Discussion with Audience Q&A
Presenters: Somjot S. Brar, Bruce
R. Brodie, Giuseppe De Luca, Dariusz Dudek, Cindy L. Grines,
Jose PS Henriques, Laura Mauri, Christian M. Spaulding
|
Session III. DES Safety Considerations
DES Thrombosis
Moderators: Donald Cutlip, Ron Waksman
| 12:15pm |
|
Pathologic Predictors of DES Thrombosis: Results from a Large
Necropsy Experience
Presenter: Renu Virmani
|
| 12:25pm |
|
DES Thrombosis in Clinical Trials: Frequency and Predictors
Presenter: Laura Mauri
|
| 12:35pm |
|
DES Thrombosis in the Real World: Frequency and Clinical Predictors
Presenter: Peter Wenaweser
|
| 12:45pm |
|
Discussion with Audience Q&A
Presenters: Donald Cutlip, Laura
Mauri, Renu Virmani, Ron Waksman, Peter Wenaweser
|
Dual Antiplatelet Considerations
Moderators: Gilles Montalescot, Daniel I. Simon
| 12:55pm |
|
Point-of-Care Platelet Assays and Aspirin/Thienopyridine Hyporesponsiveness:
DES Thrombosis in Aspirin and Clopidogrel Hyporesponders
Presenter:
David Antoniucci
|
| 1:05pm |
|
Point-of-Care Platelet Assays and Aspirin/Thienopyridine Hyporesponsiveness
Prasugrel Decisions: When to Consider in Non-ACS Patients (Complex
DES? Clopidogrel Hyporesponders? After Stent Thrombosis?)
Presenter:
C. Michael Gibson
|
| 1:15pm |
|
Point-of-Care Platelet Assays and Aspirin/Thienopyridine Hyporesponsiveness:
Recommendations for Testing and (if you Test) Managing DAPT Hyporesponders:
1. After DES thrombosis; 2. High-risk patients; 3. Routine patients
Presenter:
George D. Dangas
|
| 1:25pm |
|
Point-of-Care Platelet Assays and Aspirin/Thienopyridine Hyporesponsiveness:
Cilostazol, an Alternative or Additive Antiplatelet Agent for
Hyporesponders or High-Risk Patients to Reduce DES Thrombosis?
Presenter:
Seung-Whan Lee
|
| 1:35pm |
|
Flash Debate 2, Duration of DAPT: In Most DES Patients, the
Duration of DAPT should Be . . . One Year (or Indefinitely)!
Presenter:
Dominick J. Angiolillo
|
| 1:43pm |
|
Flash Debate 2, Duration of DAPT: In Most DES Patients, the
Duration of DAPT should Be . . . Six Months at Most!
Presenter:
Stephan Windecker
|
| 1:51pm |
|
Discussion with Audience Q&A
Presenters: Dominick J. Angiolillo,
David Antoniucci, George D. Dangas, C. Michael Gibson, Paul A.
Gurbel, Seung-Whan Lee, Gilles Montalescot, Daniel I. Simon
|
| 2:03pm |
|
Updates from Ongoing DAPT Studies: United States: ADAPT-DES
Registry
Presenter: Gregg W. Stone
|
| 2:08pm |
|
Updates from Ongoing DAPT Studies: United States: PARIS Registry
Presenter:
Roxana Mehran
|
| 2:13pm |
|
Updates from Ongoing DAPT Studies: United States: GRAVITAS
Randomized Trial
Presenter: Paul S. Teirstein
|
| 2:18pm |
|
Updates from Ongoing DAPT Studies: Germany: ISAR-SAFE
Presenter:
Adnan Kastrati
|
| 2:23pm |
|
Updates from Ongoing DAPT Studies: Germany: TRIGGER-PCI
Presenter:
Franz-Josef Neumann
|
| 2:28pm |
|
Updates from Ongoing DAPT Studies: Brazil: OPTIMIZE Randomized
Trial
Presenter: Fausto Feres
|
| 2:33pm |
|
Updates from Ongoing DAPT Studies: United States: DAPT Randomized
Trial
Presenter: Laura Mauri
|
Surrogate Safety Endpoints
Moderators: Renu Virmani, Alan C. Yeung
| 2:38pm |
|
Coronary Vasomotion Studies in Patients with DES: Methodology,
Pathophysiology, Clinical Implications, and Differences Among
DES
Presenter: Stephan Windecker
|
| 2:48pm |
|
Coronary Angioscopy in Patients with DES: Analysis of Neointimal
Coverage and Differences Among DES
Presenter: Masaki Awata
|
| 2:58pm |
|
Serial Coronary OCT Studies in Patients with DES: Assessments
of Healing Responses and Differences Among DES
Presenter: Giulio
Guagliumi
|
| 3:08pm |
|
Insights from Serial IVUS Studies in Patients with DES: Pathobiologic
Responses and Predictors of Late Stent Thrombosis
Presenter:
Gary S. Mintz
|
| 3:18pm |
|
Discussion with Audience Q&A
Presenters: Masaki Awata, Giulio
Guagliumi, Gary S. Mintz, Renu Virmani, Alan C. Yeung
|
Session IV. DES Efficacy
and "Durability" Considerations
Jean
Fajadet, Adnan Kastrati
DES Efficacy . . . DES In-Stent Restenosis: Mechanisms, Frequency, Clinical Outcomes,
and Treatment Alternatives
Lecturer: Ron Waksman
Flash Debate 3: Are There Important Antirestenosis Differences Among DES?
| 3:40pm |
|
Angiographic Perspectives
Presenter: Alexandra J. Lansky
|
| 3:48pm |
|
IVUS Perspectives
Presenter: Peter J. Fitzgerald
|
| 3:58pm |
|
Clinical Perspectives
Presenter: Adrian P. Banning
|
| 4:04pm |
|
Discussion with Audience Q&A
Presenters: Adrian P. Banning,
Jean Fajadet, Peter J. Fitzgerald, Adnan Kastrati, Alexandra
J. Lansky
|
DES "Durability" . . . Strut Fractures
After DES Implantation: Mechanisms, Frequency, Device Specificity,
and Clinical Consequences
Lecturer:
Akiko Maehara
Flash Debate 4: Are DES (vs. BMS) Associated
with Late"Catch-up" and Durability
Concerns?
| 4:24pm |
|
Without Doubt, Look at the Pathology!
Presenter: Renu Virmani
|
| 4:32pm |
|
For Certain, Look at Serial Angiographic Studies!
Presenter:
Julinda Mehilli
|
| 4:40pm |
|
Not at All, Look at Five-Year Clinical Follow-up from Blinded
Randomized
Trials!
Presenter: Donald Cutlip
|
| 4:48pm |
|
Discussion with Audience Q&A
Presenters: Donald Cutlip, Jean
Fajadet, Adnan Kastrati, Akiko Maehara, Julinda Mehilli, Renu
Virmani
|
Session V. Current Generation DES
| 4:58pm |
|
The CYPHER Sirolimus-Eluting Stent: Comprehensive Update of
the Clinical Trial Program
Lecturer: Daniel I. Simon
|
| 5:13pm |
|
The TAXUS Paclitaxel-Eluting Stent: Final Five-Year Results of the TAXUS
Express SR Program, New Insights from TAXUS Libert, and Progress with
TAXUS and Everolimus ELEMENT
Lecturer: Stephen G. Ellis
|
| 5:28pm |
|
The ENDEAVOR and ENDEAVOR Resolute Zotarolimus-Eluting Stent: Comprehensive
Update of the Clinical Trial Program (Featuring the First Presentation
of the ENDEAVOR IV 3-Year Results)
Lecturer: Martin B. Leon
|
| 5:43pm |
|
The XIENCE V/PROMUS Everolimus-Eluting Stent: Comprehensive Update of
the Clinical Trial Program (Featuring the First Presentation of the SPIRIT
III Three-Year Results)
Lecturer: Gregg W. Stone
|
| 5:58pm |
|
Clinical and angiographic results from a randomized trial of sirolimus-eluting
and everolimus-eluting stents: ISAR-TEST 4
Lecturer: Adnan Kastrati
|
| 6:06pm |
|
The NOBURI Biolimus-Eluting Stent: Comprehensive Update of the Clinical
Trial Program
Lecturer: Bernard R. Chevalier
|
| 6:16pm |
|
The BIOMATRIX Biolimus-Eluting Stent: Comprehensive Update of the Clinical
Trial Program
Lecturer: Stephan Windecker
|
| 6:24pm |
|
Discussion with Audience Q&A
Panel
Moderators: Stephen G. Ellis, Alan
C. Yeung
Discussants: Bernard R. Chevalier, Adnan Kastrati, Martin B.
Leon, Daniel I. Simon, Gregg W. Stone, Stephan Windecker |
The Drug-Eluting Stent Summit Part 2:
Tomorrow's Technology
Tuesday,
September 22, 2009 -- 1:00pm -6:30pm
Room: 104
Session I. Limitations of Today's DES Technology
| 1:00pm |
|
Why Next Generation DES Are Needed: Experimental Horrors
Lecturer: Renu
Virmani
|
| 1:08pm |
|
Why Next Generation DES Are Needed: Clinical Inadequacies and Disappointments
Lecturer: Antonio Colombo
|
| 1:16pm |
|
Can a Pro-Healing Stent Make a Difference? Final 12-Month Outcomes From
the e-HEALING 5,000 Patient Registry Using the EPC-Coated Genous Stent
Lecturer: Robert J. de Winter
|
| 1:24pm |
|
Transformational Approaches to Evaluating Tomorrow's DES Technology
Lecturer: Greg L. Kaluza
|
| 1:32pm |
|
Discussion with Audience Q&A
Panel Moderators: Nicolas A. F. Chronos,
Robert S. Schwartz
Discussants: Antonio Colombo, Robert J. de Winter,
Greg L. Kaluza, Renu Virmani
|
Session II. Bioabsorbable DES Platforms
| 1:40pm |
|
The Boston Scientific JACTAX Paclitaxel-Eluting Stent Program (Ultra-Thin
Ablumenal PLA Polymer): Focus on the Randomized OCTDESI Strut Coverage
Evaluation
Lecturer: Giulio Guagliumi
|
| 1:50pm |
|
The Cordis NEVO Sirolimus-Eluting Stent Program (PLGA Absorbable
Polymer-Drug Reservoirs)
Lecturer: John A. Ormiston
|
| 2:00pm |
|
The Shahajanand SUPRALIMUS Sirolimus-Eluting Stent Program (Multilayered
Absorbable Polymer)
Lecturer: Pedro A. Lemos
|
| 2:08pm |
|
The BIOMINE Sirolimus-Eluting Stent Program (Meril Lifescience Absorbable
Polymer)
Lecturer: Ashok Seth
|
| 2:16pm |
|
The Elixir Bioabsorbable Polymer Myolimus-Eluting Stent Program
Lecturer:
Bernhard Witzenbichler
|
| 2:23pm |
|
The Elixir Bioabsorbable Polymer Novolimus-Eluting Stent Program
Lecturer:
Alexandre Abizaid
|
| 2:31pm |
|
The Orbus-Neich EPC-Coated Bioabsorbable Polymer Sirolimus-Eluting
Stent Program
Lecturer: Juan F. Granada
|
| 2:39pm |
|
The Cardiomind SPARROW DES Program (CARE II): A Bioabsorbable
Polymer Sirolimus-Eluting "Micro-Stent"
Lecturer: Roberto Botelho
|
| 2:47pm |
|
Polymer Bioabsorption Fundamentals and Differences Among DES Systems
Lecturer: Elazer R. Edelman
|
| 2:57pm |
|
Discussion with Audience Q&A
Panel Moderators: Peter J. Fitzgerald,
Renu Virmani
Discussants: Alexandre Abizaid, Roberto Botelho, Elazer
R. Edelman, Juan F. Granada, Giulio Guagliumi, Pedro A. Lemos, John
A. Ormiston, Ashok Seth, Bernhard Witzenbichler
|
Session III. Polymer-Free DES Platforms
| 3:07pm |
|
Are Polymer-Free DES Systems Safer? Observations from Experimental
Studies in Animal Models
Lecturer: Renu Virmani
|
| 3:15pm |
|
The Biosensors BIOFREEDOM Polymer-Free Biolimus-Eluting Stent Program
Lecturer: Joachim Schofer
|
| 3:23pm |
|
The MinVasys Amazonia PAX and BIPAX Polymer-Free Paclitaxel-Eluting
Stent Program
Lecturer: Jean Fajadet
|
| 3:31pm |
|
The MIV VESTASYNC Polymer-Free Sirolimus-Eluting Stent Program (Micorporous
Hydroxyapatite Surface)
Lecturer: Alexandre Abizaid
|
| 3:39pm |
|
The ISAR Polymer-Free Single and Dual Drug-Eluting Stent Programs
(Sirolimus and Probucol)
Lecturer: Helmut Schuhlen
|
| 3:47pm |
|
The CID OPTIMA Polymer-Free Tacrolimus-Eluting Stent Program (Ablumenal
Grooves)
Lecturer: Alexandre Abizaid
|
| 3:55pm |
|
The Medinol Polymer-Free Ridaforolimus-Eluting Stent Program (Gas
Cluster Ion Bombardment)
Lecturer: Yoram Richter
|
| 4:03pm |
|
Discussion with Audience Q&A
Panel Moderators: Elazer R. Edelman,
Ross Prpic
Discussants: Alexandre Abizaid, Jean Fajadet, Adnan Kastrati,
Yoram Richter, Joachim Schofer, Helmut Schuhlen, TBA, Renu Virmani
|
Session IV. Hot Topics I: Fully Bioabsorbable Stents
| 4:13pm |
|
The Challenges of Developing a Fully Bioabsorbable Stent
Lecturer:
Robert S. Schwartz
|
| 4:21pm |
|
The Abbott BVS Fully Resorbable PLLA Everolimus-Eluting Stent 1:
Device Evolution and Three-Year Clinical Outcomes with the Cohort A
Device
Lecturer: John A. Ormiston
|
| 4:31pm |
|
The Abbott BVS Fully Resorbable PLLA Everolimus-Eluting Stent 2:
Serial Angiography, IVUS, and OCT Imaging Studies with the Cohort A
Device
Lecturer: Patrick W. Serruys
|
| 4:41pm |
|
The REVA Tyrosine-Derived Polycarbonate Bioabsorbable Stent: Lessons
Learned and Future Directions
Lecturer: Alexandre Abizaid
|
| 4:51pm |
|
The BTI Salicylate-Based Polyanhydride Ester Bioabosrbable Sirolimus-Eluting
Stent Program: Lessons Learned and Future Directions
Lecturer: Refat
Jabara
|
| 5:01pm |
|
The Biotronik Magnesium Alloy Bioabsorbable Stent Program: Lessons
Learned and Future Directions
Lecturer: Ron Waksman
|
| 5:11pm |
|
Discussion with Audience Q&A
Panel Moderators: Edoardo Camenzind,
Ian T. Meredith
Discussants: Alexandre Abizaid, Refat Jabara, John
A. Ormiston, Robert S. Schwartz, Patrick W. Serruys, Ron Waksman |
Session V. Hot Topics II: Drug-Eluting Balloons
| 5:21pm |
|
Dissecting the Drug-Eluting Balloon Multifaceted Puzzle: Drug Delivery
and Retention, Mechanistic Considerations, and Vascular Biology - Experimental
Observations
Lecturer: Juan F. Granada
|
| 5:31pm |
|
Pioneers' Perspectives: The Design Requirements for a Successful
Drug-Eluting Balloon
Lecturer: Bruno Scheller
|
| 5:41pm |
|
The PEPCAD V Bifurcation Study: Results from a Paclitaxel-Eluting
Balloon for Bifurcation Coronary Lesions
Lecturer: Detlef G. Mathey
|
| 5:51pm |
|
Summarizing the B. Braun PEPCAD Coronary Paclitaxel-Eluting Balloon
Clinical Studies
Lecturer: Martin Unverdorben
|
| 6:01pm |
|
Summarizing the Use of Drug-Eluting Balloons for Endovascular Applications
(THUNDER Trial and Others)
Lecturer: Barry T. Katzen
|
| 6:11pm |
|
Discussion with Audience Q&A: Future Expectations and Directions
for Drug-Eluting Balloon Technology
Panel Moderators: Juan F. Granada,
Bruno Scheller
Discussants: Barry T. Katzen, Detlef G. Mathey, Martin
Unverdorben
|
Source: Transcatheter
Cardiovascular Therapeutics (TCT)
|
